Key result
Cascade genetic testing defines childhood cardiac penetrance and outcomes in LMNA variant carriers.
Why the study?
Pediatric data on isolated LMNA cardiomyopathy are lacking, and the clinical benefit of family screening and cascade genetic testing in pediatric first-degree relatives has not been systematically evaluated.
What is the cardiac penetrance and clinical yield of family screening and cascade genetic testing in children with LMNA variants?
Cohort
Yes
What is the cardiac penetrance and clinical yield of family screening and cascade genetic testing in children with LMNA variants?
This multicenter study investigates the previously uncharacterized pediatric cardiac penetrance and clinical outcomes of isolated LMNA cardiomyopathy to evaluate the yield of family screening in children.
Answers are grounded in this paper and cite their sources.
Pediatric LMNA screening data remain limited; leaves open optimal cascade testing yield and timing in children.
amin A/C (LMNA) variants have autosomal dominant inheritance and wide phenotypic heterogeneity, including neuromuscular and cardiac disease.Cardiac manifestations include structural and electrical disease; LMNA variants are considered high-risk genotypes associated with sudden cardiac death. 1 Isolated LMNA cardiomyopathy, without neuromuscular involvement, is considered a disease most relevant to the adult population, with complete penetrance by 60 years, 2 but pediatric data are lacking.Clinical family screening and cascade genetic testing are recommended in pediatric first-degree relatives regardless of age. 1 However, the clinical benefit of this approach for LMNA cardiomyopathy specifically has not been systematically evaluated.We aimed to explore the cardiac phenotype and outcomes in children with LMNA variants and investigate cardiac penetrance in pediatric genotypepositive relatives.This study complied with the Declaration of Helsinki and the study protocols were approved by the ethics committee of each site.
No takes yet. Share an insight, caveat, or question.
Smedsrud et al. (2026) conducted a cohort in Isolated Lamin A/C (LMNA) cardiomyopathy. Clinical family screening and cascade genetic testing for LMNA variants was evaluated on Cardiac phenotype, outcomes, and cardiac penetrance. Clinical family screening and cascade genetic testing were evaluated for cardiac penetrance and outcomes in children with LMNA variants (no quantitative results reported in excerpt).
Synapse has enriched 10 related papers. Consider them for comparative context: